Yield Growth Corp. (
CSE:BOSS,
OTCQB:BOSQF,
Forum) announced on Thursday that its majority owned subsidiary
NeonMind has entered into an agreement entitled with
Translational Life Sciences Inc. to begin clinical tests of potential therapeutic effects of psilocybin and other compounds in psychedelic mushrooms.
To learn more about the timely product approval,
click here.
BOSS recently
changed the name of this subsidiary to
NeonMind Biosciences Inc. from
Flourish Mushroom Labs Inc., a company engaged in research and development of potentially therapeutic uses of psychedelic mushrooms and development of functional mushroom products.
FULL DISCLOSURE: Yield Growth Corp. is a client of Stockhouse Publishing.